Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125562102 | 12556210 | 2 | F | 20160818 | 20160714 | 20160825 | EXP | CA-PFIZER INC-2015268970 | PFIZER | 51.00 | YR | F | Y | 0.00000 | 20160825 | MD | CA | CA |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125562102 | 12556210 | 1 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 20 MG, WEEKLY | N | 11719 | 20 | MG | TABLET | /wk | |||||
125562102 | 12556210 | 2 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 15 MG, WEEKLY | N | 11719 | 15 | MG | TABLET | /wk | |||||
125562102 | 12556210 | 3 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Subcutaneous | 25 MG, UNK | N | 11719 | 25 | MG | SOLUTION FOR INJECTION | ||||||
125562102 | 12556210 | 4 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Subcutaneous | 25 UNK, UNK | N | 11719 | 25 | MG | SOLUTION FOR INJECTION | ||||||
125562102 | 12556210 | 5 | SS | SULFASALAZINE. | SULFASALAZINE | 1 | Oral | 1 G, DAILY | N | 7073 | 1 | G | |||||||
125562102 | 12556210 | 6 | SS | PLAQUENIL | HYDROXYCHLOROQUINE SULFATE | 1 | 200 MG, 2X/DAY | N | 0 | 200 | MG | TABLET | BID | ||||||
125562102 | 12556210 | 7 | SS | PLAQUENIL | HYDROXYCHLOROQUINE SULFATE | 1 | UNK | N | 0 | TABLET | |||||||||
125562102 | 12556210 | 8 | SS | PLAQUENIL | HYDROXYCHLOROQUINE SULFATE | 1 | 200 MG, DAILY | N | 0 | 200 | MG | TABLET | |||||||
125562102 | 12556210 | 9 | C | FOLIC ACID. | FOLIC ACID | 1 | 5 MG, WEEKLY | 0 | 5 | MG | TABLET | /wk | |||||||
125562102 | 12556210 | 10 | C | NAPROSYN | NAPROXEN | 1 | Oral | 500 MG, 2X/DAY | 0 | 500 | MG | BID | |||||||
125562102 | 12556210 | 11 | C | TYLENOL WITH CODEINE | ACETAMINOPHENCODEINE PHOSPHATE | 1 | UNK | 0 | |||||||||||
125562102 | 12556210 | 12 | C | VIMOVO | ESOMEPRAZOLE MAGNESIUMNAPROXEN | 1 | 500/20 MG (1 TABLET) TWO TIMES DAILY | 0 | 1 | DF | TABLET | BID | |||||||
125562102 | 12556210 | 13 | C | MELOXICAM. | MELOXICAM | 1 | 150 MG, DAILY | 0 | 150 | MG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125562102 | 12556210 | 1 | Rheumatoid arthritis |
125562102 | 12556210 | 3 | Rheumatoid arthritis |
125562102 | 12556210 | 6 | Rheumatoid arthritis |
125562102 | 12556210 | 12 | Rheumatoid arthritis |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125562102 | 12556210 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125562102 | 12556210 | Axillary mass | |
125562102 | 12556210 | Condition aggravated | |
125562102 | 12556210 | Drug hypersensitivity | |
125562102 | 12556210 | Drug intolerance | |
125562102 | 12556210 | Dry mouth | |
125562102 | 12556210 | Interstitial lung disease | |
125562102 | 12556210 | Ocular hyperaemia | |
125562102 | 12556210 | Photophobia | |
125562102 | 12556210 | Rash | |
125562102 | 12556210 | Rash pruritic | |
125562102 | 12556210 | Rheumatoid arthritis |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125562102 | 12556210 | 1 | 200710 | 2008 | 0 | |
125562102 | 12556210 | 3 | 20080314 | 200806 | 0 | |
125562102 | 12556210 | 4 | 2014 | 0 | ||
125562102 | 12556210 | 5 | 20071221 | 20080211 | 0 | |
125562102 | 12556210 | 6 | 200711 | 200804 | 0 | |
125562102 | 12556210 | 7 | 201409 | 0 |